Just a few years since pioneering a Covid-19 vaccine, Moderna faces a hostile political environment and a looming patent ...

Before joining Moderna, Cronin spent close to 20 years at Ogilvy, working within its global healthcare department in ...

We recently published a list of Did Jim Cramer Nail or Miss These 14 Stocks? In this article, we are going to take a look at ...

Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

The United States led the world in developing the technology that beat the COVID-19 pandemic. Action from lawmakers may leave ...

Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $70.0 for Moderna over the recent three months. In terms of liquidity ...

The Trump administration’s decision to cut funding for Gavi, as part of a broader reduction in foreign aid, may have significant implications for vaccine makers. The move is expected to scale back ...

Citi analyst Geoff Meacham reiterated a Hold rating on Moderna (MRNA – Research Report) yesterday and set a price target of $40.00. The ...

Is it time to average down on a Moderna holding or begin a new position? Let's look at the company's recent performance and ...

Paula Newton speaks with co-founder and Chair of Moderna, Noubar Afeyan, about his hopes for the release of Ruben Vardanyan, ...